PFG Investments LLC Raises Stock Position in iShares Biotechnology ETF (NASDAQ:IBB)

PFG Investments LLC lifted its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 7.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 9,319 shares of the financial services provider’s stock after buying an additional 661 shares during the period. PFG Investments LLC’s holdings in iShares Biotechnology ETF were worth $1,232,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of IBB. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF in the third quarter worth approximately $29,000. Highline Wealth Partners LLC bought a new stake in iShares Biotechnology ETF during the third quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new position in iShares Biotechnology ETF in the third quarter worth about $36,000. Modus Advisors LLC bought a new position in shares of iShares Biotechnology ETF during the 4th quarter worth approximately $41,000. Finally, Voisard Asset Management Group Inc. acquired a new position in shares of iShares Biotechnology ETF during the third quarter worth $59,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 0.8 %

iShares Biotechnology ETF stock opened at $138.37 on Tuesday. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The stock has a 50-day moving average of $136.15 and a two-hundred day moving average of $141.77.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.